10 results about "Neurogenic inflammation" patented technology

Disclosed are therapeutic methods comprising the delivery of particular substituted pyridine based compounds for lowering intracranial pressure (ICP) and / or lowering neurogenic inflammation in treating substance P mediated pathways in the brain such as, but not limited to concussion, post-concussive (or post-concussion) syndrome (PCS), traumatic brain injury (TBI) and stroke.

The invention discloses a diamino tetrahydropyran compound, a composition and application of the diamino tetrahydropyran compound, and belongs to the field of chemical medicines. The invention provides a diamine tetrahydropyran compound as shown in a formula (I), or pharmaceutically acceptable salt, prodrug, hydrate or solvent compound, crystal form, stereoisomer or isotope variant thereof, which can be used for preventing and inhibiting neurogenic inflammation, and is used for treating and / or preventing urticaria itching, angioedema and other related diseases.

WATER-SOLUBLE EXTRACT FROM A PLANT OF THE PRUNUS SPECIES TO PREVENT THE DELETE EFFECTS OF THE EXPOSOME. The present invention relates to the use of a flower extract from a plant of the Rosaceae family and the Prunus genus, or a composition thereof, to protect the skin from the deleterious effects of the exposome, including disruption of the barrier function, neurogenic inflammation, irritation, and oxidative stress. The invention is thus intended to prevent the clinical signs of premature aging, including the appearance of hyperpigmentation spots responsible for loss of skin tone uniformity and skin hyperreactivity.

The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof:The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.

The invention relates to the technical field of skin care, in particular to a plant extract for inhibiting TRPV1 receptors and relieving and a preparation method thereof.The plant extract is prepared by extracting portulaca oleracea, rosemary leaves and citrus peel according to the weight ratio of (1-3): (1-5): (0.1-0.2), and the citrus peel is dried peel of sweet oranges, grapefruits or lemons. The preparation method comprises the steps of raw material pretreatment, extraction solvent preparation, extraction and post-treatment, according to the plant extract capable of inhibiting the TRPV1 receptor and relieving and the preparation method thereof, the purslane, the rosemary leaves and the citrus peel are combined according to the specific weight ratio of (1-3): (1-5): (0.1-0.2), flavone and alkaloid in the purslane, carnosic acid and rosmarinic acid in the rosemary, carnosic acid and rosmarinic acid in the rosemary and the citrus peel are mixed, and the TRPV1 receptor inhibiting and relieving plant extract is obtained. Three active ingredients of polymethoxylated flavonoids in the citrus peel form a synergistic effect, so that activation of a key receptor TRPV1 of skin itch and stabbing pain is directly inhibited from the upstream, neurogenic inflammation is blocked from the source, expression of core inflammatory factors such as TNF-alpha and IL-6 is synergistically inhibited from the downstream, and the effect of the composition is superior to that of a single plant extract and a mixture with a non-optimal ratio.

The invention relates to the technical field of medicine health, in particular to a traditional Chinese medicine composition and a pharmaceutical preparation for treating migraine. The traditional Chinese medicine composition comprises ligusticum wallichii, notopterygium root, radix angelicae, asarum, radix bupleuri, fructus viticis, fried tribulus terrestris, schizonepeta, cimicifugae foetidae, rhizoma atractylodis, lotus leaf and divaricate saposhnikovia root. The traditional Chinese medicine composition provided by the invention has the effects of improving neurogenic inflammation, regulating blood vessels and relieving pain, and has a good treatment effect on migraine.

The present application relates to the technical field of medicine, and more particularly to a polypeptide for inhibiting and / or eliminating beta-amyloid aggregation and application thereof. The present application first develops a functional active polypeptide ANI-1 which can act on diseases caused by beta-amyloid aggregation and deposition such as Alzheimer's disease from multiple targets, so as to effectively prevent and treat the diseases. The polypeptide ANI-1 of the present application has the functions of eliminating A beta aggregation, delaying behavioral decline caused by beta-amyloid toxicity (anti-paralysis, promoting movement), inhibiting neurogenic inflammation related to beta-amyloid deposition and enhancing antioxidant defense, has better overall efficacy and neuroprotective potential, and can provide a new idea for developing a multi-target drug for diseases caused by beta-amyloid aggregation and deposition such as Alzheimer's disease.

This invention relates to the field of pharmaceutical technology, disclosing the application of *Melastoma candida* polysaccharide in the preparation of drugs for the prevention or treatment of chronic urticaria. This invention is the first to discover that *Melastoma candida* polysaccharide can regulate immune homeostasis, inhibit inflammatory responses, improve skin lesions, and restore intestinal flora balance through multiple pathways. It also inhibits the overactivation of the NGF / TRPV1 / p38 signaling pathway, reduces neurogenic inflammation and mast cell-mediated responses, thereby alleviating the pathological process of chronic urticaria. This broadens the application scope of *Melastoma candida* polysaccharide and provides a new approach for the treatment of allergic skin-related diseases.

The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof:The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, cough, itch, and neurogenic inflammation.

The invention discloses a lactobacillus gasseri BDUP (Lactobacillus gasseri) strain and application of the lactobacillus gasseri BDUP strain in preparation of drugs for treating atopic dermatitis or eczema. The preservation number of the lactobacillus gasseri BDUP strain is CGMCC (China General Microbiological Culture Collection Center) No. 18357. Different from existing probiotics which take effect mainly by resisting histamine or regulating Th1 / Th2 balance, the invention discloses a unique nerve-immune bidirectional regulation mechanism of the BDUP strain for the first time, and the BDUP strain can significantly down-regulate expression levels of a neuropeptide P substance (Substance P), a calcitonin gene-related peptide (CGRP), a nerve growth factor (NGF) and a pruritus specific factor IL-31 in skin tissues, so that the BDUP strain can be used for treating skin pruritus. Therefore, neurogenic inflammation and a pruritus conduction pathway are effectively blocked. Animal experiments show that the BDUP strain can shorten the scratching time of eczema model mice by about 80%, the itching relieving and anti-inflammatory effects of the BDUP strain are equivalent to those of potent glucocorticoid, and the BDUP strain has no side effect. The invention provides a novel efficient biological treatment scheme for solving intractable pruritus caused by eczema.